Guildford, UK, 29 July 2011: ReNeuron announces that its Annual Report and Accounts for the year ended 31 March 2011 and the Notice of the 2011 Annual General Meeting (AGM) have been sent to shareholders and are also available on the Company’s website at https://www.reneuron.com/financial-reports
Guildford, UK, 20 July 2011: ReNeuron announces that it is strengthening its Board by the appointments of
Please click on link below for webcast of 2011 Preliminary results presentation to analysts. .
http://mediaserve.buchanan.uk.com/2011/reneuron300611/registrationasp
Guildford, UK, 5 July 2011: ReNeuron announces that it has signed a new contract with Angel Biotechnology for development and GMP (Good Manufacturing Practice) manufacturing services in support of its development programme for its ReN001 stem cell therapy for stroke.
Guildford, UK, 30 June 2011: ReNeuron announces Preliminary Results for the Year Ended March 2011
Guildford, UK, 24 June 2011: ReNeuron announces that it is launching a newly designed corporate website. The website has enhanced layout and content, reflecting the Company’s progress, ambition and leading position in the development of novel stem cell therapeutics for stroke and other significant disease conditions.
The new website will go live over this coming weekend, the precise timing from the user’s perspective being subject to some variation depending on the user’s internet service provider. Subscribers to the Company’s email alert service are requested to re-subscribe on the new website to ensure continuing provision of email press release alerts.
There is no change to the Company’s website address, which remains as https://www.reneuron.com
Guildford, UK, 16 June 2011: ReNeuron Group plc (LSE: RENE.L) (“ReNeuron” or the “Company”) announces that it has signed a patent and know-how license agreement with Schepens Eye Research Institute (“Schepens”), Boston, US, regarding the Company’s ReN003 stem cell therapy programme focused on diseases of the retina.
Guildford, UK, 27 May 2011: ReNeuron Group plc (LSE: RENE.L) is pleased to announce the completion of dosing of the first cohort of patients in the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. The PISCES clinical trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.
Guildford, UK, 18 May 2011: ReNeuron Group plc (LSE: RENE.L) announces that it is participating in the 17th International Society for Cellular Therapy Annual Meeting in Rotterdam, Netherlands on 18-21 May.
Guildford, UK, 11 May 2011: ReNeuron Group plc (LSE: RENE.L) welcomes yesterday’s launch by the Technology Strategy Board of the first stage in the creation of a UK technology and innovation centre to support the development and commercialisation of cell therapies and advanced therapeutics.
